trichostatin-a and Epstein-Barr-Virus-Infections

trichostatin-a has been researched along with Epstein-Barr-Virus-Infections* in 3 studies

Other Studies

3 other study(ies) available for trichostatin-a and Epstein-Barr-Virus-Infections

ArticleYear
Identification of genes specifically methylated in Epstein-Barr virus-associated gastric carcinomas.
    Cancer science, 2013, Volume: 104, Issue:10

    We studied the comprehensive DNA methylation status in the naturally derived gastric adenocarcinoma cell line SNU-719, which was infected with the Epstein-Barr virus (EBV) by methylated CpG island recovery on chip assay. To identify genes specifically methylated in EBV-associated gastric carcinomas (EBVaGC), we focused on seven genes, TP73, BLU, FSD1, BCL7A, MARK1, SCRN1, and NKX3.1, based on the results of methylated CpG island recovery on chip assay. We confirmed DNA methylation of the genes by methylation-specific PCR and bisulfite sequencing in SNU-719. The expression of the genes, except for BCL7A, was upregulated by a combination of 5-Aza-2'-deoxycytidine and trichostatin A treatment in SNU-719. After the treatment, unmethylated DNA became detectable in all seven genes by methylation-specific PCR. We verified DNA methylation of the genes in 75 primary gastric cancer tissues from 25 patients with EBVaGC and 50 EBV-negative patients who were controls. The methylation frequencies of TP73, BLU, FSD1, BCL7A, MARK1, SCRN1, and NKX3.1 were significantly higher in EBVaGC than in EBV-negative gastric carcinoma. We identified seven genes with promoter regions that were specifically methylated in EBVaGC. Inactivation of these genes may suppress their function as tumor suppressor genes or tumor-associated antigens and help to develop and maintain EBVaGC.

    Topics: Aged; Azacitidine; Carcinoma; Cell Line, Tumor; Cytoskeletal Proteins; Decitabine; DNA Methylation; DNA-Binding Proteins; DNA, Neoplasm; Epstein-Barr Virus Infections; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Homeodomain Proteins; Humans; Hydroxamic Acids; Male; Microfilament Proteins; Middle Aged; Neoplasm Proteins; Nerve Tissue Proteins; Nuclear Proteins; Oncogene Proteins; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Real-Time Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Stomach Neoplasms; Transcription Factors; Tumor Protein p73; Tumor Suppressor Proteins

2013
Enforced expression of RASAL1 suppresses cell proliferation and the transformation ability of gastric cancer cells.
    Oncology reports, 2012, Volume: 28, Issue:4

    RAS protein activator like 1 (RASAL1) is a member of the RAS GTPase-activating protein (GAP) family, and it is an important molecule in the regulation of RAS activation. In the present study, we investigated the role of RASAL1 in gastric carcinogenesis. Decreased expression pattern of RASAL1 in gastric cancer tissues and cell lines was found in protein and RNA levels, although there was no statistically significant relationship between RASAL1 and clinicopathological features. Restored expression of RASAL1 induced by DNA methylation inhibitor 5-aza-2'-deoxycytidine (5'-AZA) and HDAC inhibitor trichostatin A (TSA) implied that RASAL1 expression is regulated by epigenetic mechanisms. The biological role of RASAL1 in gastric carcinogenesis was determined by in vitro tumorigenicity assays. Overexpression of RASAL1 showed suppression of cell proliferation due to cell apoptosis. Subsequently, enforced expression of RASAL1 repressed significantly the gastric cancer cell transformation ability. These findings demonstrated that decreased RASAL1 expression is a characteristic of gastric cancer and regulated by epigenetic mechanisms. RASAL1 may be a functional tumor suppressor involved in gastric cancer. This study provides novel insights into the biological role of RASAL1 in gastric carcinogenesis.

    Topics: Aged; Azacitidine; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Epigenesis, Genetic; Epstein-Barr Virus Infections; Female; Gene Expression Regulation, Neoplastic; GTPase-Activating Proteins; Helicobacter Infections; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Middle Aged; ras GTPase-Activating Proteins; Stomach Neoplasms

2012
Interplay between PKCδ and Sp1 on histone deacetylase inhibitor-mediated Epstein-Barr virus reactivation.
    Journal of virology, 2011, Volume: 85, Issue:5

    Epstein-Barr virus (EBV) undergoes latent and lytic replication cycles, and its reactivation from latency to lytic replication is initiated by expression of the two viral immediate-early transactivators, Zta and Rta. In vitro, reactivation of EBV can be induced by anti-immunoglobulin, tetradecanoyl phorbol acetate, and histone deacetylase inhibitor (HDACi). We have discovered that protein kinase C delta (PKCδ) is required specifically for EBV reactivation by HDACi. Overexpression of PKCδ is sufficient to induce the activity of the Zta promoter (Zp) but not of the Rta promoter (Rp). Deletion analysis revealed that the ZID element of Zp is important for PKCδ activation. Moreover, the Sp1 putative sequence on ZID is essential for PKCδ-induced Zp activity, and the physiological binding of Sp1 on ZID has been confirmed. After HDACi treatment, activated PKCδ can phosphorylate Sp1 at serine residues and might result in dissociation of the HDAC2 repressor from ZID. HDACi-mediated HDAC2-Sp1 dissociation can be inhibited by the PKCδ inhibitor, Rotterlin. Furthermore, overexpression of HDAC2 can suppress the HDACi-induced Zp activity. Consequently, we hypothesize that HDACi induces PKCδ activation, causing phosphorylation of Sp1, and that the interplay between PKCδ and Sp1 results in the release of HDAC2 repressor from Zp and initiation of Zta expression.

    Topics: Cell Line; Epstein-Barr Virus Infections; Gene Expression Regulation, Viral; Herpesvirus 4, Human; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immediate-Early Proteins; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Protein Kinase C-delta; Sp1 Transcription Factor; Trans-Activators; Virus Activation

2011